Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.88, while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $96.26M). The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| GSG | INO | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $2.87 |
52-Week Low | $22.06 | $1.05 |
Market Cap | — | $96.26M |
Enterprise Value | — | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $30.85, down 0.48% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though oscillators are neutral and short-term RSI signals suggest overbought conditions. Recent financial media highlights a thematic focus on commodities as a key market driver, with notable investors increasing exposure to the sector.
The outlook for GSG is tied to commodity price trends and broader economic developments. Investment opportunity lies in exposure to a constrained supply environment and inflation hedging. Primary risks include commodity price volatility, global economic slowdowns reducing demand, and the ETF's structure leading to tracking error or contango in futures markets.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
